BioRegenx Reports Improved Net Loss of $26,415 Amid Revenue Decline

BioRegenx, Inc. reported a net loss of $26,415 for the three months ended March 31, 2026, a significant improvement compared to a net loss of $266,854 during the same period in 2025. The company generated net sales of $426,175, reflecting a 17% decrease from $515,147 in the prior year. This decline in revenue was attributed to product issues with the medical testing machine, which adversely affected sales of nutritional products. Despite the drop in sales, the cost of goods sold decreased by 29% to $77,887, resulting in a gross profit of $348,288, down 14% from $406,031 in the previous year.

Operationally, BioRegenx has made strategic adjustments, including a reduction in distributor incentives, which fell by 80% to $1,658. Total operating expenses decreased by 34% to $398,052, primarily due to lower selling, general, and administrative expenses, which were down 33% to $396,394. The company also reported other income of $100,435, which included recoveries from bad debts and write-offs of accrued expenses. The overall reduction in expenses contributed to a 74% improvement in loss from operations, which was recorded at $(49,764) compared to $(192,615) in the prior year.

As of March 31, 2026, BioRegenx faced significant financial challenges, including a stockholder's deficit of $4,533,316 and cash on hand of only $45,806. The company has been reliant on raising funds through equity offerings and borrowings to sustain operations, raising substantial doubt about its ability to continue as a going concern. Notably, the company has defaulted on notes payable totaling $522,500, which includes two unsecured promissory notes and Economic Injury Disaster Loans (EIDL) totaling $400,000. Management is actively pursuing financing alternatives to address these challenges.

In terms of operational metrics, the company continues to focus on its core business of developing and manufacturing medical test equipment and nutritional products. The recent acquisition of DocSun Biomedical Holdings, Inc. is expected to enhance its product offerings and distribution capabilities. However, the company has not reported any significant changes in customer counts or geographic expansion during this period. The employee headcount remains stable, with no major organizational changes noted in the filing.

Looking ahead, BioRegenx anticipates the need for additional capital to fund ongoing operations and develop its business further. The management has indicated that it may utilize a combination of equity and debt instruments or enter into strategic arrangements to secure necessary funding. However, there is no assurance that such financing will be available or that it will be on favorable terms. The company remains committed to addressing its financial challenges while continuing to pursue its operational goals.